What's Behind Jazz Pharmaceuticals' Q2 Revenue and Earnings Beats
Jazz Pharmaceuticals (NASDAQ: JAZZ) hasn't given investors much good news so far in 2020. The drugmaker's first-quarter results announced in May were disappointing. Jazz stock has dropped 23% year to date.
But Jazz appears to be hitting more right notes now. The company announced its second-quarter results after the market closed on Tuesday. Here are the highlights from Jazz's Q2 update.
Image Source: Getty Images.
Source Fool.com
